A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins

被引:79
作者
Bredenbeek, PJ
Molenkamp, R
Spaan, WJM
Deubel, V
Marianneau, P
Salvato, MS
Moshkoff, D
Zapata, J
Tikhonov, C
Patterson, J
Carrion, R
Ticer, A
Brasky, K
Lukashevich, IS [1 ]
机构
[1] Univ Maryland, Inst Biotechnol, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA
[2] SW Fdn Biomed Res, Dept Virol & Immunol, San Antonio, TX 78245 USA
[3] Leiden Univ, Med Ctr, Ctr Infect Dis, Dept Med Microbiol, Leiden, Netherlands
[4] Ctr Rech Meriuex Pasteur Lyon, Unite Biol Infect Emergentes, Lab Jean Merieux P4, Lyon, France
关键词
yellow and lassa fevers; YFV17D vaccine; recombinant vaccine;
D O I
10.1016/j.virol.2005.12.001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Yellow Fever Vaccine 17D (YFV17D) has been used as a vector for the Lassa virus glycoprotein precursor (LASV-GPC) resulting ill construction of YFV17D/LASV-GPC recombinant Virus. The virus was replication-competent and processed the LASV-GPC ill Cell Cultures. The recombinant replicated poorly in guinea pigs but Still elicited specific antibodies against LASV and YFV17D antigens. A single subcutaneous injection of the recombinant vaccine protected strain 13 guinea pigs against fatal Lassa Fever. This Study demonstrates the potential to develop an YFV17D-based bivalent vaccine against two viruses that are endemic in the same area of Africa. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:299 / 304
页数:6
相关论文
共 20 条
[1]  
[Anonymous], 2004, VACCINES-BASEL
[2]   Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes [J].
Barba-Spaeth, G ;
Longman, RS ;
Albert, ML ;
Rice, CM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (09) :1179-1184
[3]   Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface [J].
Bonaldo, MC ;
Garratt, RC ;
Marchevsky, RS ;
Coutinho, ESF ;
Jabor, AV ;
Almeida, LFC ;
Yamamura, AMY ;
Duarte, AS ;
Oliveira, PJ ;
Lizeu, JOP ;
Camacho, LAB ;
Freire, MS ;
Galler, R .
JOURNAL OF VIROLOGY, 2005, 79 (13) :8602-8613
[4]   Hemorrhagic fever viruses as biological weapons - Medical and public health management [J].
Borio, L ;
Inglesby, T ;
Peters, CJ ;
Schmaljohn, AL ;
Hughes, JM ;
Jahrling, PB ;
Ksiazek, T ;
Johnson, KM ;
Meyerhoff, A ;
O'Toole, T ;
Ascher, MS ;
Bartlett, J ;
Breman, JG ;
Eitzen, EM ;
Hamburg, M ;
Hauer, J ;
Henderson, A ;
Johnson, RT ;
Kwik, G ;
Layton, M ;
Lillibridge, S ;
Nabel, GJ ;
Osterholm, MT ;
Perl, TM ;
Russell, P ;
Tonat, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (18) :2391-2405
[5]   A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication [J].
Bredenbeek, PJ ;
Kooi, EA ;
Lindenbach, B ;
Huijkman, N ;
Rice, CM ;
Spaan, WJM .
JOURNAL OF GENERAL VIROLOGY, 2003, 84 :1261-1268
[6]   Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor [J].
Eichler, R ;
Lenz, O ;
Strecker, T ;
Eickmann, M ;
Klenk, HD ;
Garten, W .
EMBO REPORTS, 2003, 4 (11) :1084-1088
[7]  
Fisher-Hoch S.P., 2004, EXPERT REV VACCINES, V3, P103, DOI DOI 10.1586/14760584.3.2.189
[8]   Development of a new vaccine for the prevention of lassa fever [J].
Geisbert, TW ;
Jones, S ;
Fritz, EA ;
Shurtleff, AC ;
Geisbert, JB ;
Liebscher, R ;
Grolla, A ;
Ströher, U ;
Fernando, L ;
Daddario, KM ;
Guttieri, MC ;
Mothé, BR ;
Larsen, T ;
Hensley, LE ;
Jahrling, PB ;
Feldmann, H .
PLOS MEDICINE, 2005, 2 (06) :537-545
[9]   Imported Lassa fever in Germany:: Molecular characterization of a new Lassa virus strain [J].
Günther, S ;
Emmerich, P ;
Laue, T ;
Kühle, O ;
Asper, M ;
Jung, A ;
Grewing, T ;
ter Meulen, J ;
Schmitz, H .
EMERGING INFECTIOUS DISEASES, 2000, 6 (05) :466-476
[10]   Identification of a novel consensus sequence at the cleavage site of the lassa virus glycoprotein [J].
Lenz, O ;
ter Meulen, J ;
Feldmann, H ;
Klenk, HD ;
Garten, W .
JOURNAL OF VIROLOGY, 2000, 74 (23) :11418-11421